News articles about Arena Pharmaceuticals (NASDAQ:ARNA) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Arena Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.2329027619382 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media headlines that may have effected Accern Sentiment’s analysis:
- ARENA PHARMACEUTICALS, INC. (ARNA) (4-traders.com)
- Here’s What Lifted Arena Pharmaceuticals, Inc. Stock in September – Motley Fool (fool.com)
- Stock recommendation to Buy: Arena Pharmaceuticals, Inc. (ARNA) – Street Observer (press release) (streetobserver.com)
- Here’s What Lifted Arena Pharmaceuticals, Inc. Stock in September – nwitimes.com (nwitimes.com)
- Zacks: Brokerages Anticipate Arena Pharmaceuticals, Inc. (ARNA) Will Post Quarterly Sales of $4.39 Million (americanbankingnews.com)
ARNA has been the subject of a number of recent analyst reports. Citigroup Inc. upped their price target on shares of Arena Pharmaceuticals from $23.00 to $37.00 and gave the company a “buy” rating in a report on Tuesday, July 11th. Zacks Investment Research upgraded shares of Arena Pharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a report on Tuesday, July 4th. Cantor Fitzgerald reiterated a “buy” rating and set a $37.00 price target on shares of Arena Pharmaceuticals in a report on Monday, September 25th. ValuEngine upgraded shares of Arena Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Finally, BidaskClub upgraded shares of Arena Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, July 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $36.00.
Arena Pharmaceuticals (ARNA) opened at 26.44 on Thursday. Arena Pharmaceuticals has a one year low of $11.30 and a one year high of $27.86. The company’s market capitalization is $1.04 billion. The firm has a 50-day moving average of $24.37 and a 200 day moving average of $18.64.
Arena Pharmaceuticals (NASDAQ:ARNA) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.03). Arena Pharmaceuticals had a negative return on equity of 49.87% and a negative net margin of 16.27%. The business had revenue of $6.49 million for the quarter, compared to the consensus estimate of $5.58 million. During the same quarter last year, the business posted ($1.10) earnings per share. The firm’s revenue for the quarter was down 31.8% compared to the same quarter last year. Equities research analysts predict that Arena Pharmaceuticals will post ($2.94) earnings per share for the current fiscal year.
Arena Pharmaceuticals Company Profile
Arena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).
What are top analysts saying about Arena Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Arena Pharmaceuticals Inc. and related companies.